Anti-CD20 Reference Antibody (divozilimab) is used as a standard in the development and evaluation of therapeutic antibodies targeting B cells, particularly in research and quality control of biological products. It facilitates the assessment of specificity, concentration, and activity of commercial antibodies directed against the CD20 protein on B-cell surfaces. This antibody plays a crucial role in supporting the development of treatments for autoimmune disorders and B-cell malignancies, such as leukemia and lymphoma, serving as a reference to ensure the accuracy and consistency of laboratory test results.